MX2024006505A - Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia. - Google Patents
Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia.Info
- Publication number
- MX2024006505A MX2024006505A MX2024006505A MX2024006505A MX2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A MX 2024006505 A MX2024006505 A MX 2024006505A
- Authority
- MX
- Mexico
- Prior art keywords
- dementia
- methods
- symptoms associated
- behavioral symptoms
- agitation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283696P | 2021-11-29 | 2021-11-29 | |
| PCT/US2022/079861 WO2023097151A1 (en) | 2021-11-29 | 2022-11-15 | Methods of treating agitation and other dementia-associated behavioral symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006505A true MX2024006505A (es) | 2024-06-05 |
Family
ID=86540411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006505A MX2024006505A (es) | 2021-11-29 | 2022-11-15 | Metodos para tratar la agitacion y otros sintomas conductuales asociados con la demencia. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20240423998A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4440566A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024544500A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118354769A (cg-RX-API-DMAC10.html) |
| CA (1) | CA3236462A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024006505A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023097151A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| WO2025024104A2 (en) * | 2023-07-06 | 2025-01-30 | Woolsey Pharmaceuticals, Inc. | Method for reducing caregiver burden associated with alzheimer's disease |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0104340D0 (sv) * | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| EP2061314A4 (en) | 2006-08-10 | 2010-08-04 | Translational Genomics Res Inst | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| US20080044390A1 (en) | 2006-08-11 | 2008-02-21 | Xiaowei Jin | Methods and compositions for the treatment of neurodegenerative disorders |
| CN101612157A (zh) | 2008-06-26 | 2009-12-30 | 天津红日药业股份有限公司 | 法舒地尔诱导成年脑内源性神经干细胞再生的用途 |
| EP2825175B1 (en) | 2012-03-12 | 2017-07-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| US9617214B2 (en) * | 2013-11-08 | 2017-04-11 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
| US10537567B2 (en) * | 2017-07-11 | 2020-01-21 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
| CN111050766A (zh) * | 2017-07-21 | 2020-04-21 | 卡德门企业有限公司 | Rho相关含卷曲螺旋蛋白激酶的抑制剂 |
| EP3868408A4 (en) | 2018-10-15 | 2022-07-06 | National University Corporation Tokai National Higher Education and Research System | ANTISYCHOTIC AND ITS USE |
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| US11642352B2 (en) | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
| CA3169944A1 (en) | 2020-03-25 | 2021-09-30 | Thomas Macallister | Methods of using rho kinase inhibitors to treat frontotemporal dementia |
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| WO2021257122A1 (en) | 2020-06-15 | 2021-12-23 | Woolsey Pharmaceuticals, Inc | Methods of using rho kinase inhibitors to treat vascular dementia |
| EP4171564A4 (en) | 2020-06-25 | 2024-06-26 | Woolsey Pharmaceuticals, Inc. | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS |
| EP4181925A4 (en) | 2020-07-14 | 2024-07-31 | Woolsey Pharmaceuticals, Inc. | METHODS OF TREATMENT OF PROTEINOPATHIES |
| US11311553B1 (en) | 2020-10-22 | 2022-04-26 | Woolsey Pharmaceuticals, Inc. | Methods of treating 4-repeat tauopathies |
| US20220331333A1 (en) | 2021-04-16 | 2022-10-20 | Universite De Strasbourg | Rhoa pathway inhibitor in the treatment of neurodevelopmental disorder or neuropsychiatric disorder |
| WO2022245708A1 (en) | 2021-05-19 | 2022-11-24 | Woolsey Pharmaceuticals, Inc. | Methods of treating depression and anxiety |
| MX2023013538A (es) | 2021-05-19 | 2023-11-27 | Woolsey Pharmaceuticals Inc | Metodos para tratar la depresion y la ansiedad. |
-
2022
- 2022-11-15 WO PCT/US2022/079861 patent/WO2023097151A1/en not_active Ceased
- 2022-11-15 US US18/712,654 patent/US20240423998A1/en active Pending
- 2022-11-15 EP EP22899474.5A patent/EP4440566A4/en not_active Withdrawn
- 2022-11-15 CN CN202280078331.XA patent/CN118354769A/zh active Pending
- 2022-11-15 MX MX2024006505A patent/MX2024006505A/es unknown
- 2022-11-15 CA CA3236462A patent/CA3236462A1/en active Pending
- 2022-11-15 JP JP2024526913A patent/JP2024544500A/ja active Pending
-
2023
- 2023-03-02 US US18/177,188 patent/US11865119B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023097151A1 (en) | 2023-06-01 |
| JP2024544500A (ja) | 2024-12-03 |
| EP4440566A4 (en) | 2025-10-01 |
| US11865119B2 (en) | 2024-01-09 |
| CN118354769A (zh) | 2024-07-16 |
| EP4440566A1 (en) | 2024-10-09 |
| CA3236462A1 (en) | 2023-06-01 |
| US20230201219A1 (en) | 2023-06-29 |
| US20240423998A1 (en) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005011A (es) | Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7). | |
| UA102669C2 (xx) | Застосування інгібіторів dpp iv$применение ингибиторов dpp iv | |
| ATE527016T1 (de) | System zur überwachung oder behandlung von erkrankungen des nervensystems | |
| EP4288048A4 (en) | OXA-IBOGAIN-INSPIRED ANALOGUES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | |
| CY1124762T1 (el) | Αναστολεις πρωτεïνης δεσμευσης creb (cbp) | |
| Jincai et al. | Effects of vinpocetine and ozagrel on behavioral recovery of rats after global brain ischemia | |
| CY1107204T1 (el) | Πιπεραζινοβενζοθειαζολια ως ουσιες για την θεραπευτικη αντιμετωπιση εγκεφαλικων ισχαιμικων διαταραχων ή διαταραχων του κνς | |
| EA202092557A1 (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРОБЕНЗОФУРО[2,3-c]ПИРИДИНА И БЕТА-КАРБОЛИНА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ-БЕЛКА | |
| BR112016006154A2 (pt) | derivados de indol e indazol | |
| Park et al. | Effects of Acupuncture on Alzheimer’s Disease in Animal‐Based Research | |
| EP4288075A4 (en) | SELECTIVE INHIBITION OF ROCK2 FOR THE TREATMENT OF EDEMA AND RELATED CONDITIONS | |
| JOP20250210A1 (ar) | مثبطات الكيناز المعتمدة على السيكلين (cdk2) | |
| MX2022010456A (es) | Compuestos heterocíclicos para modular la subfamilia de receptores nucleares 2, grupo f, miembro 6. | |
| EP4251753A4 (en) | TREATMENT OF DISEASES AND DISORDERS RELATED TO SOS2 | |
| BR112019024878A2 (pt) | Agente para prevenção ou tratamento de tauopatia | |
| EP4561695A4 (en) | PHOTOTHERAPY DEVICE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EA202190406A1 (ru) | Способы лечения нейродегенеративных расстройств | |
| EP4326327A4 (en) | Ubiquitin-Specific Peptidase 22 Inhibitors and Their Uses in the Treatment of Diseases and Disorders | |
| EP4355430A4 (en) | TREATMENT OF DISEASES AND DISORDERS RELATED TO MST1R | |
| Stanton | The Chinese Ear Shenmen Point and the French Cosmonaut Point: Same or Different? | |
| MX2022014356A (es) | Ciertas composiciones quimicas y metodos de uso de las mismas. | |
| EP4112120A4 (en) | APPARATUS AND SYSTEM FOR GENERATING AN ALTERNATIVE MAGNETIC FIELD FOR THE TREATMENT OF DISEASES | |
| JOP20240149A1 (ar) | مثبطات bcl-2 (الخلية ب لمفومة 2) | |
| CO2023016081A2 (es) | Composición farmacéutica para prevenir o tratar una enfermedad cerebral y alimento funcional de salud para prevenir o aliviar una enfermedad cerebral que la comprende | |
| EP4447952A4 (en) | Benzoic acid salts for the treatment of injuries and disorders of the nervous system |